Concord Biotech (CONCORDBIO) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 revenue grew 14% year-over-year, led by strong API segment performance and improved order execution following regulatory approvals.

• WHO GMP certification for the injectable facility enables domestic and emerging market sales, with peak revenue potential estimated at INR 600 crore.

• New subsidiaries established in India and the US, including Concord Lifegen and Stellon Biotech, to strengthen global expansion and commercialization.

• Unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, were approved without audit qualifications.

• FY26 expected to remain below historical averages, but normalization and growth are anticipated from FY27 onward.

Financial highlights

• Q3 FY26 revenue: INR 278 crore (14% YoY growth); nine-month revenue: INR 729 crore (5% YoY decline); consolidated Q3 revenue: INR 277.8 crore.

• API revenue in Q3: INR 219 crore (24% YoY growth); Formulation revenue: INR 58 crore (down from INR 68 crore YoY).

• Q3 EBITDA: INR 99 crore (margin 35.6%), impacted by startup costs; normalized margin at 40%.

• Q3 profit after tax: INR 64 crore (Q3 FY25: INR 76 crore), affected by new labor costs and lower other income.

• Zero debt; cash and equivalents at INR 350 crore as of December 2025.

Outlook and guidance

• Q4 expected to be stronger, with gradual normalization of margins as injectables scale up.

• Management expects continued demand growth, higher order inflows, and increased CDMO engagements, supported by positive trade dynamics and regulatory clarity.

• Historical CAGR of 18% targeted, with potential to reach 25% as new growth drivers mature.

• The company continues to monitor regulatory changes, especially regarding the new Labour Codes.